

EXHIBIT 5

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

Plaintiff's list of objections to Defendant's trial exhibits corresponds to the abbreviations identified in the table below. Plaintiff also reserves the right to object to any exhibit offered by Defendant at trial that is not on its exhibit list.

- R** = Irrelevant (FRE 401-402)

A = Unauthenticated (Rule 901)

DU = Duplicative

F = Lack of foundation
- H** = Hearsay (FRE 801 and 802)

C = Completeness

U = Unfairly prejudicial, confusing and/or waste of time (FRE

NPI = Documents that are not properly identified. The objecting party reserves the right to further object after inspection or examination of the properly identified documents.

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
1	301 - Mathiowitz 349 - Foster Bodmeier Expert Report - A Bodmeier 2 Expert Report - A Bolton Declaration - B Bolton Expert Report - B Meyer Expert Report - C	9/19/2006	Certified U.S. Patent No. 7,108,866			NPI		

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
2	38 - Maes 103 - Deboeck 342 - Davies Bodmeier Expert Declaration - C Niemczyk Expert Declaration - C Porter Expert Report - B Weiner Expert Report - D	6/25/1996	Certified U.S. Patent No. 5,529,791			NPI		
3	39 - Maes	12/17/1999	Certified File Wrapper: Application No. 09/465,338			NPI		
4	Bodmeier Expert Report - Q	9/19/2006	Certified File Wrapper: Application No. 09/567,451; Patent No. 7,108,866			NPI		
5		3/9/2006	Certified File Wrapper: Application No. 11/370,842					
6		6/25/1996	Certified File Wrapper: Application No. 08/311,722; Patent No. 5,529,791					
7	Bodmeier Expert Declaration - L Porter Expert Report - C	2/28/1989	Certified U.S. Patent No. 4,808,413			NPI		
8	Bodmeier Expert Declaration - N Porter Expert Report - E	1/16/1990	Certified U.S. Patent No. 4,894,240			NPI		

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
9	Bodmeier Expert Declaration - M Porter Expert Report - D	10/2/1990	Certified U.S. Patent No. 4,960,596			NPI		
10	Bodmeier Expert Report - D Meyer Expert Report - N	3/26/1991	Certified U.S. Patent No. 5,002,776			NPI		
11	Bodmeier Expert Report - C	2/22/1994	Certified U.S. Patent No. 5,288,505			NPI		
12		7/13/2006	Certified Pre-Grant Publication No. U.S. 2006/0153914 A1					
13	1 - Hopkins	11/16/2005	Biovail Pharmaceuticals, Inc.; Biovail Pharmaceuticals Canada; Nutravail Technologies, Inc. - Organizational Charts	BLS 010066	BLS 010076	R, U		
14	2 - Hopkins 2A - Smith	2005/00/00	Cardizem LA Contribution	BLS 022200				
15	3 - Hopkins 3A - Smith	2003-2006	Sale Charts	BLS 021059	BLS 021068			
16	4 - Hopkins 4A - Smith	2/18/2003	Letter from Douglas Baratta of Biovail announcing the launch of Cardizem LA	BLS 022195	BLS 022197	R, H		
17	5 - Hopkins	5/3/2005	Letter from Richard King of KOS Pharmaceuticals regarding acquired rights to products from Biovail Corporation	BLS 022201	BLS 022202	R, H		
18	6 - Hopkins 158 - Kreppner	11/15/2002	Facsimile from Denise Hinton to Wayne Kreppner regarding attaching teleconference minutes between Biovail and the FDA for September 25, 2002 meeting	BLS 009116	BLS 009119	R, U, H		
19	7 - Hopkins 161 - Kreppner	3/27/2003	Letter from Shannon Benedetto to Leigh Vaughan of the Department of Health & Human Services regarding Cardizem LA ((No Suggestions) HCL) extended-release tablets	BLS 009062	BLS 009066	R, U, H		
20	8 - Hopkins 8A - Smith 187 - Kreppner	2/20/2003	Letter from Kevin McDonald of Biovail to Douglas Throckmorton regarding NDA 21-392 Cardizem LA ((No Suggestions) HCL) Extended-Release Tablets proposed promotional launch campaign and attaching proposed promotional and advertising materials	BLS 022203	BLS 022374	R, U, H		

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
21	9 - Hopkins 9A - Smith 160 - Kreppner	9/15/2004	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use (PM dosing makes the AM difference - Cardizem LA)	BLS 022930	BLS 022938	R		
22	10 - Hopkins	9/20/2004	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use (Cardizem LA delivers ...)	BLS 022944	BLS 022946	R		
23	11 - Hopkins 183 - Kreppner	12/15/2004	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use (Antihypertensive Efficacy of Night-Time Graded-Release Diltiazem Versus Morning Amlodipine in African Americans)	BLS 023263	BLS 023278	R		
24	12 - Hopkins 12A - Smith	1/17/2005	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use (Hypertension and the Importance of Chronobiology to Treatment)	BLS 023365	BLS 023405	R		
25	13 - Hopkins	5/11/2006	Cardizemla.com website page (Cardizem LA: learn about managing your blood pressure)					
26	14 - Hopkins 48 - Khairo	2/27/2006	Biovail's Second Supplemental Responses to Defendant Andrx's Interrogatory Nos. 1-4 and 6-8					
27	15 - Reininghaus	3/8/1991	Letter from Arthur Deboeck, Vice President of Galephar to Rolf Reininghaus regarding the registration and licensing of Diltiazem Once Daily product	ANDCLA 15970		R, U, H		
28	16 - Reininghaus	3/4/1991	Facsimile from Rolf Reininghaus to Arthur Deboeck regarding synopsis of the revised terms and conditions of the proposed licensing agreement for SUPPRESSAN CR	ANDCLA 15966	ANDCLA 15969	R, U, H		
29	17 - Reininghaus	2/18/1991	Letter from Arthur Deboeck, Vice President of Galephar to Rolf Reininghaus responding to February 1, 1991 letter regarding Suppressan E.R. (Diltiazem once daily)	ANDCLA 15955	ANDCLA 15960	R, U, H		
30	18 - Reininghaus	1/14/1993	Diltiazem - G01 - NDA Meeting (January 14-15, 1993). The objective is NDA - Chemistry & Manufacturing Milestone Plan through review of data from clinical batches, commercial production plan and finalizing action plan	ANDCLA 15937	ANDCLA 15938	R, U, H		

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
31	19 - Reininghaus	2/8/1993	Minutes: Ted Wood of BMPC, Hans Neuer and Roger Croswell conducted the meeting. Other people in attendance: Mike Vanzielegghem, Rolf Reininghaus, Jim Doran, Michael Latta, Ray Spruzenieks and Bruce Brydon. Other issues addressed were: manufacturing concerns regarding patent issues relating to the active material; mutual cooperation is desired for filing and processing the product.	ANDCLA 15931	ANDCLA 15936	R, U, H		
32	20 - Reininghaus	2/14/1993	Minutes of Boehringer Mannheim/Biovail Meeting. People in attendance: Mike Vanzielegghem, Rolf Reininghaus, Jim Doran, Michael Latta, B. Bozogany, T. Williamson, H-J Schuster, H. Neuer, J. Miszuk, D. Deeth, M. Brennan, C. Mills, R. Burford, Melnyk. The meeting discussed market potential for (No Suggestions) SR OD, key terms for proposed licensing agreement, action plan for license agreement.	ANDCLA 15975	ANDCLA 15977	R, U, H		
33	21 - Reininghaus	12/12/1992	Memorandum from Rolf Reininghaus to Mike Vanzielegghem regarding Diltiazem SR #G01 and whether or not to present this data to the FDA	ANDCLA 16003		R, U, H		
34	22 - Reininghaus	12/30/1992	Memorandum from Dr. K. K. Midha to Mike Van in response to memo from December 16, 1992 regarding discrepancies in bioavailability between Biovail Diltiazem once a day and Cardizem CD	ANDCLA 16004		R, U, H		
35	23 - Reininghaus	1/28/1993	Letter from Elliot Hahn, President of Andrx Corporation to Rolf Reininghaus regarding meeting on Monday and the signing of Biovail's Non/Disclosure Agreement and Andrx Confidentiality Agreement	ANDCLA 38877		R, U, H		
36	24 - Reininghaus	1997/00/00	Biovail 1997 Annual Report	ANDCLA 22627	ANDCLA 22674			
37	25 - Reininghaus	6/30/1993	Rights Agreement by and between Biovail Research Corporation and Hoechst-Roussel Pharmaceuticals	ANDCLA 25021	ANDCLA 25043			
38	26 - Reininghaus	10/2/2003	Memorandum from Georgina Butler to John Miszuk regarding Biovail/Galephar Agreements with Attachments	BLS 026166	BLS 026223			
39	27 - Reininghaus	10/2/2003	Memorandum from Georgina Butler to John Miszuk regarding Biovail/Galephar Agreements with Attachments	BLS 026166	BLS 026223	R, U, H		
40	28 - Maes	5/2/2006	Letter from Preston Ratliff II to Steve Maddox regarding Biovail's witness designations					

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
41	29 - Maes	5/1/2006	Biovail's objections to Andrx's Notice of 30(b)(6) deposition of Biovail Laboratories International SRL					
42	31 - Maes	7/21/2001	Biovail Laboratory Notebook (Fuisz Technologies Ltd.) No. 1212	BLS 017891	BLS 018062	R, U, H		
43	32 - Maes	8/22/2001	NDA 21-420 Cardizem NT 240 mg, 300 mg and 360 mg - Volume 3 of 167	BLS 014205 BLS 014227 BLS 014258 BLS 014325 BLS 014466 BLS 014504 BLS 014626 BLS 014632	BLS 014250 BLS 014260 BLS 014327 BLS 014468 BLS 014505	NPI, C		
44	34 - Maes	11/5/2001	Biovail Development Reports Volume 1, G99 - Product Development Report for Diltiazem HCL Extended Release Bead Tablet	BLS 010501	BLS 010852			
45	35 - Maes	6/11/2001	Biovail - NDA 21-392 Diltiazem Hydrochloride Extended Release Tablets 240 mg, 300 mg, 360 mg - Volume 1 of 48	BLS 000183 BLS 000195 BLS 000214 BLS 000255 BLS 000295 BLS 000314	BLS 000187 BLS 000226 BLS 000281 BLS 000312			
46	36 - Maes	0000/00/00	Biovail - NDA 21-392 Diltiazem Hydrochloride Extended Release Tablets 240 mg, 300 mg, 360 mg - Volume 3 of 48	BLS 000661 BLS 000668 BLS 000767	BLS 000691 BLS 000769	NPI, C		
47	37 - Maes	3/27/2002	Biovail - Product Development Report for the Diltiazem HCL Extended Release Bead Coated Tablets, 120, 180, and 420 mg	BLS 009843	BLS 009933			
48	40 - Maes	5/8/2000	File Wrapper for Abandoned U.S. Application No. 09/567,451 - Chronotherapeutic Diltiazem Formulations and the Administration Thereof	ANDCLA 35611	ANDCLA 35716	C		
49	41 - Maes	12/8/1998	Biovail - Solubility of Diltiazem in Water and Sucrose Solution	B 013998	B 014000			
50	42 - Maes	1998/00/00	Suleiman, et al., Stability of Diltiazem hydrochloride in Aqueous Sugar Solutions, Journal of Clinical Pharmacy and Therapeutics 13, 417-422	A 14868	A 14873			

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
51	43 - Khairo	4/6/2006	Andrx's Notice of 30 (b)(6) Deposition of Biovail Laboratories International SRL					
52	44 - Khairo	11/1/2005	Andrx's First Request for the Production of Documents and Things to Biovail			U		
53	45 - Khairo	5/1/2006	Biovail's Objections to Andrx's Notice of 30(b)(6) Deposition of Biovail Laboratories International SRL			U		
54	46 - Khairo	12/23/2005	Biovail's Responses to Defendant Andrx's First Set of Interrogatories			U		
55	47 - Khairo	1/20/2006	Biovail's Supplemental Responses to Defendant Andrx's Interrogatory Nos. 1 and 4			U		
56			EXHIBIT REMOVED			U		
57	101 - Deboeck	12/15/2005	Subpoena and Document Request for Deposition - Galephar P.R., Inc. Ltd.			U		
58	102 - Deboeck	12/14/2006	Subpoena and Document Request for Deposition - Arthur M. Deboeck			U		
59	104 - Deboeck	0000/00/00	Resume of Arthur M. Deboeck	ANDCLA 18860	ANDCLA 18865			
60	105 - Deboeck 30 - Maes 1001 - Maes Bodmeier Expert Report - B Meyer Expert Report - Y	9/18/1997	Diltiazem ER Capsules Product Development Report	BLS 026482	BLS 026699			
61	106 - Deboeck	2/3/1999	U.S. Patent Application No. 08/311,722 Extended-Release Form of Diltiazem	ANDCLA 16246	ANDCLA 16363	C		
62	107 - Deboeck	9/14/1999	U.S. Patent Application No. 07/721,396 Extended-Release Form of Diltiazem	ANDCLA 16365	ANDCLA 16544	C		
63	120 - Smith	2004/04/00	Revised product insert for Cardizem LA					
64	121 - Smith	2005/05/00	Biovail 2005 Annual Report					
65	122 - Smith 162 - Kreppner	9/4/2001	FDA Contact Report - telephone meeting with Laurie Burke and Wayne Kreppner regarding Cardizem NT - NDA 21-420	BLS 009199		R, U, H		

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
66	123 - Smith	8/21/2003	Letter from Beth Ferguson, Biovail to Douglas Throckmorton, FDA regarding Amendment to Supplement for NDA 21-392 Cardizem LA, S-002 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, and 420 mg	BLS 009343		R, U, H		
67	124 - Smith 159 - Kreppner	7/22/2004	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use (Cardizem LA)	BLS 022791	BLS 022824	R		
68	150 - Kreppner	5/21/2002	Faxed Letter from HHS to Biovail regarding CMC Deficiencies NDA 21-392	BLS 006933	BLS 006938	R, U, H		
69	151 - Kreppner	3/23/2001	Letter from HHS to Biovail regarding the '463 patent	ANDCLA 39407	ANDCLA 39412	R, U, H		
70	152 - Kreppner	2/12/2002	Cardizem Launch Readiness Assessment Discussion - Draft	BLS 018347	BLS 018377	R, U, H		
71	153 - Kreppner	4/16/2003	Biovail FDA Contact Report for Project: Cardizem LA Tablet NDA 21-392	BLS 009051		R, U, H		
72	154 - Kreppner	1/16/2002	Letter from Wayne Kreppner to R.J. Lipicky, FDA regarding <i>In vitro/In vivo</i> Correlation Study Data for NDA 21-392 Cardizem NT 120, 180, 240, 300, 350 and 420 mg Diltiazem Hydrochloride Extended- Release Tablets - Amendment to pending application	BLS 006779		R, U, H		
73	155 - Kreppner	3/8/2002	Letter from Wayne Kreppner to R.J. Lipicky, FDA regarding <i>In vitro/In vivo</i> Correlation Study Data for NDA 21-392 Cardizem NT 120, 180, 240, 300, 350 and 420 mg Diltiazem Hydrochloride Extended-Release Tablets - Amendment to pending application	BLS 006789		R, U, H		
74	156 - Kreppner	11/2/2001	Letter from Wayne Kreppner to Dr. Norman Stockbridge, FDA regarding NDA 21-392 - Financial Disclosure	BLS 009190 BLS 009193		R, U, H		
75	157 - Kreppner	1/10/2003	Biovail Weekly Project Status Report - G99B1 Technology Transfer	BLS 018853	BLS 018855	R, U, H		
76	163 - Kreppner	3/18/2003	FDA Contact Report Project: Cardizem LA regarding revised 14 hours dissolution specification	BLS 009070		R, U		
77	164 - Kreppner	8/26/1999	Minutes of a Meeting Between Biovail and the FDA regarding Pre-NDA Diltiazem Extended-Release Tablets	BLS 009224	BLS 009226	R, U, H		
78	165 - Kreppner	8/26/1999	Minutes of the Pre-NDA meeting between representatives of Biovail Corporation International and the Division of Cardio-Renal Drug Products for Diltiazem Extended-Release Bead Tablets	BLS 009227	BLS 009229	R, U, H		

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
79	166 - Kreppner	2/28/2005	Email from Debra Iorio to Linda Kunka regarding Cardizem LA NDA 21-392	BLS 009250	BLS 009251	R, U, H		
80	167 - Kreppner	1/27/2005	Email from Debra Iorio to Linda Kunka regarding Feb. 22nd Type C Meeting FDA Fax Confirming Participants	BLS 009254		R, U, H		
81	168 - Kreppner	4/2/2004	Letter from FDA to Stefan Olchaski, Biovail regarding NDA 21-392/S-002 - approved	BLS 009425	BLS 009438	R, U, H		
82	169 - Kreppner 1005 - Maes	1999/08/00	Meeting package for August 1999 meeting	BLS 009620	BLS 009664	R, U, H		
83	170 - Kreppner	5/9/2000	Clinical Research Protocol A Double-Blind, Randomized, Parallel Group, Dose Response, Multi-Center Study to Compare the Safety and Efficacy of Diltiazem HCL Extended Release Capsules (G99) to Placebo Dosed at Bedtime and to G99 Dosed in the Morning in Patients with Essential Hypertension Protocol Number: B00.CT3.0011.DIL G99	BLS 010130	BLS 010177	R, U, C		
84	171 - Kreppner	3/16/2000	Email from Theophilus Gana to Albert, Sista, Pascual, Kreppner, Woodall regarding Project Conference Call Agenda and Dial Up	BLS 012198		R, U, H		
85	172 - Kreppner	3/13/2000	Revised Project Timeline Summary Biovail G99 Phase III/IV Clinical Trials	BLS 012751		R, U, H, C		
86	173 - Kreppner	3/28/2000	Clinical Research Protocol A Double-Blind, Randomized, Placebo-Controlled, Parallel Dose Response Study to Assess the Safety and Efficacy of Delayed Release G99 In Patients with Essential Hypertension	BLS 010920	BLS 010952	R, U, C		
87	174 - Kreppner	4/14/2000	Clinical Research Protocol A Prospective, Randomized, Open-Label, Blinded-Endpoint (Probe) Design Crossover Study Comparing Diltiazem HCL Extended Release Capsules (G99) 420 MG Administered at 10 pm to Cardizem CD 420 mg Administered at 8 am in Patients with Moderate to Severe Hypertension Protocol No. B99.CT4.003.G99	BLS 012368	BLS 012412	R, U, C		
88	175 - Kreppner	8/23/2000	Biovail G99 B00.CT3.011.DIL, B00.CT3.012.DIL Team List	BLS 011517	BLS 011553	R, U, H		
89	176 - Kreppner	4/2/2002	Combined Weekly Summary for Angina - Biovail G99 Angina Trial Enrollment History	BLS 011867	BLS 011875	R, U, H		
90	177 - Kreppner	6/3/2003	Letter from Thuy T. Chua to FDA regarding Supplemental NDA 21-392 for angina indication, Cardizem LA (Diltiazem hydrochloride Extended-Release) Tablets	BLS 008653 BLS 008695	BLS 008661 BLS 008734	R, U, H		

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
91	178 - Kreppner	5/5/2000	Email from Theophilus Gana to Albert, Sista, Kreppner, Pascual, Woodall, Puzio regarding Updates for Biovail Investigators and Timelines	BLS 012759	BLS 012764	R, U, H		
92	179 - Kreppner	10/1/2001	Biovail Bid Template - Cardizem XL - Ace Comparison Trial	BLS 012796	BLS 012799	R, U, H		
93	180 - Kreppner	12/16/2004	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use - Cardizem LA	BLS 023279	BLS 023291	R		
94	181 - Kreppner	4/24/2002	Biovail/Integrated Research/STATPROBE Angina-G99 vs. Ramipril Joint Planning Meeting Minutes - April 18, 2002	BLS 012949	BLS 012951	R, U, H		
95	182 - Kreppner	10/10/2001	Clinical Research Protocol - Draft - A Multi-Center, Double-Blind, Randomized, Parallel Group, Dose-To-Effect Study to Compare the Safety and Efficacy of Bedtime Dosing of Diltiazem HCL Extended-Release Tablets (G99) and Ramipril in Patients with Mild to Moderate Essential Hypertension - Protocol No. B01.CT4.018.DIL G99	BLS 012804	BLS 012852	R, U, C		
96	184 - Kreppner	7/17/2002	Email from Robert Tyka to Shannon Woodall regarding TPD (No Suggestions) diltiazem meeting	BLS 013537		R, U, H		
97	185 - Kreppner	10/1/2001	Email from Theophilus Gana to Shannon Woodall regarding G99 Phase IV Clinical Trials - Tablet Requirements	BLS 012869	BLS 012870	R, U, H		
98	186 - Kreppner	4/21/2005	Letter from Theresa Faver, Biovail to FDA enclosing NDA #21-392 Cardizem LA Tablets ((No Suggestions) hydrochloride Amendment to Annual Report)	BLS 021069 BLS 022132	BLS 021075 BLS 022147	R, U, H		
99	188 - Kreppner	1/9/2003	Email from Shannon Woodall to Wayne Kreppner regarding G99	BLS 018321	BLS 018322	R, U, H		
100	189 - Kreppner	1/9/2003	Email from Wayne Kreppner to Shannon Woodall regarding G99	BLS 018324	BLS 018325	R, U, H		
101	190 - Kreppner	5/31/2002	Email from Mike Deagle to Shannon Woodall regarding Diltiazem Meeting Minutes	BLS 018521		R, U, H		
102	191 - Kreppner	2/26/2003	Email from Tushar Misra to Shannon Woodall regarding G99	BLS 018418		R, U, H		
103	192 - Kreppner	6/13/2002	Email from Wayne Kreppner to Mike Deagle, Shannon Woodall regarding Steering Committee Minutes - May 30th	BLS 018530	BLS 018532	R, U, H		
104	193 - Kreppner	7/2/2002	DOE - Diltiazem Beads Manufacturing Process Optimization	BLS 018606		R, U, H, C		
105	194 - Kreppner	12/23/2004	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use (Cardizem LA)	BLS 023321	BLS 023325	R		
106	195 - Kreppner	10/31/2002	Email from David Chen to Shannon Woodall regarding Diltiazem DOE update	BLS 013386		R, U, H		

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
107	196 - Kreppner	10/9/2002	Email from Heather Smith to Shannon Woodall regarding Validation Batch Lot No. 02J124 - 360 mg ER Bead Tablet Batch	BLS 013404	BLS 013405	R, U, H		
108	197 - Kreppner	8/16/2002	Email from Wayne Kreppner to Tom Heck, Ingrid Pennick-Bailey, Shannon Woodall regarding G99	BLS 013439	BLS 013440	R, U, H		
109	198 - Kreppner 33 - Maes	8/22/2001	NDA 21-420 Cardizem NT - Volume 1 of 167	BLS 013653	BLS 013920			
110	199 - Kreppner	8/22/2001	NDA 21-420 Cardizem NT - Volume 10 of 167	BLS 016756 BLS 016778 BLS 016828		NPI, C		
111	200 - Kreppner 310 - Albert	8/12/2004	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use (Cardizem LA)	BLS 022891	BLS 022903	R		
112	303 - Mathiowitz	2/23/2005	PTO Interview Summary					
113	304 - Mathiowitz	2/23/2005	PTO Interview Summary	ANDCLA 36338	ANDCLA 36339	DU		
114	311 - Albert	5/8/2003	FDA Contact Report - Cardizem LA - Angina	BLS 009045	BLS 009046	R, U, H		
115	312 - Albert	1996/00/00	The Influence of Time of Administration on the Pharmacokinetics of a Once-A-Day Diltiazem Formulation: Morning Against Bedtime, Biopharmaceutics & Drug Disposition, Vol. 17, 107-115					
116	313 - Albert	5/5/2000	Biovail Study #2293 (B00-428PK-DILG99 - A Three-way Single-dose Open-label Fasting and Fed Comparative Bioavailability Study of Diltiazem hydrochloride Extended-Release (Tiazac XL) Capsules (420 mg) Under Two Study Conditions (Morning, Evening Administration) in Normal Healthy Non-Smoking Male and Female Volunteers Vol. I of XIII	BLS 030322	BLS 030414			
117	320 - Teskin	5/3/2001	Submission to the U.S. PTO - Application No. 09/567,451 - Chronotherapeutic Diltiazem Formulations and the Administration Thereof - Response to Official Action of November 3, 2000 Amendments and Remarks	BLS 028158	BLS 028325			

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
118	321 - Teskin Bodmeier Expert Report - W Meyer Expert Report - E	2/4/2004	Submission to the U.S. PTO - Application No. 09/567,451 - Chronotherapeutic Diltiazem Formulations and the Administration Thereof - Response to Official Action of August 4, 2003 Amendments and Remarks	BLS 028546	BLS 028560			
119	322 - Teskin	3/18/2003	Submission to the U.S. PTO - Application No. 09/567,451 - Chronotherapeutic Diltiazem Formulations and the Administration Thereof - Submissions Accompanying Request for Continued Examination (RCE)	BLS 028504	BLS 028530			
120	323 - Teskin	8/12/2002	Submission to the U.S. PTO - Application No. 09/567,451 - Chronotherapeutic Diltiazem Formulations and the Administration Thereof - Response to Official Action of February 11, 2002 Amendments and Remarks	BLS 028410	BLS 028489			
121	324 - Teskin	2/15/2005	U.S. PTO - Notice of Non-Compliant Amendment - Application No. 09/465,388	BLS 027696	BLS 027697			
122	325 - Teskin	2/22/2005	Response to Notice of Non-Compliant Amendment No. 09/465,338	BLS 027698	BLS 027754			
123	328 - Teskin	9/2/2005	Office Action Summary - Application No. 09/567,451	BLS 031862	BLS 031912			
124	329 - Teskin	12/15/2005	Letter from Robin Teskin to Salim Mamajiwalla, Biovail, enclosing a copy of the Notice of Abandonment and Interview Summary	BLS 030701	BLS 030705	R, U, H		
125	330 - Teskin Meyer Expert Report - M	1/3/2006	Amendment to Claims - Application No. 09/567,451	BLS 028935	BLS 028975			
126	331 - Teskin	3/7/2006	Fax from Teskin to U.S. PTO transmitting Information Disclosure Statement - Application No. 09/567,451	BLS 028976	BLS 028980			
127	332 - Teskin	7/7/2006	Supplemental Notice of Allowability - Application No. 09/567,451	BLS 029002	BLS 029011			

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
128	333 - Teskin Bodmeier Expert Report - E	7/4/1997	O. Eradiri and K.K. Midha, Comparison of (No Suggestions) bioavailability from 3 marketed extended-release products for once daily administration: implications of chronopharmacokinetics and dynamics, International Journal of Clinical Pharmacology and Therapeutics, Vol. 35, 369-373 (1997)	BLS 030937	BLS 030941			
129	335 - Davies	1/12/2006	Letter from Preston Ratliff II To Whom it May Concern, regarding Transport of Samples for Testing in Connection with U.S. Patent Infringement Litigation enclosing pharmaceutical production samples (42 items) transported by Professor Martyn Davies	BLS 070140	BLS 070142			
130	336 - Davies	1/12/2006	Letter from Preston Ratliff II To Whom it May Concern regarding Transport of Samples for Testing in Connection with U.S. Patent Infringement Litigation enclosing pharmaceutical production samples (6 items) transported by Professor Martyn Davies	BLS 070143	BLS 070145			
131	337 - Davies	4/15/2006	Letter from Preston Ratliff II To Whom it May Concern regarding Transport of Samples for Testing in Connection with U.S. Patent Infringement Litigation enclosing pharmaceutical production samples (18 items) transported by Professor Martyn Davies	BLS 070146	BLS 070148			
132	338 - Davies	2006/05/00	Andrx laboratory notebook relating to Andrx's work on the extended-release formulations	BLS 026700	BLS 026743	NPI		
133	339 - Davies	6/21/2006	Andrx laboratory notebook relating to Andrx's work on the extended-release formulations	BLS 026744	BLS 026758	NPI		
134	340 - Davies 350 - Foster 363 - Brenner	6/22/2007	Order Construing the Terms of U.S. Patent Nos. 5,529,791 and 7,108,866					
135	341 - Davies	2007/00/00	Stipulation and Order regarding '791 patent term "each bead"					
136	343 - Davies	9/11/2006	Expert Declaration of Chuan-Yu Wu, Ph.D. with Exhibits A - F			U, H		
137	344 - Davies	8/30/2006	Expert Declaration of Professor Thomas Niemczyk, Ph.D. with Exhibits A - G			U, H		
138	345 - Davies	10/17/2006	Supplementary Expert Declaration of Professor Thomas Niemczyk, Ph.D. with Exhibits 1 - 8			U, H		
139	352 - Foster	3/13/2007	Deposition Transcript of Alan Copa					

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
140	353 - Foster Meyer Expert Report - X	12/12/1996	Biovail Study No. 1791 A two-way, single-dose, open-label fasting comparative bioavailability study of Diltiazem HCl extended-release 300 mg capsules versus Cardizem CD 300 capsules in normal healthy non-smoking male volunteers	BLS 061424	BLS 061476	R, U		
141	354 - Foster	0000/00/00	Handwritten document by Foster of the Cmax and AUC value for the Andrx product on Document No. ANDCLA 001050					
142	355 - Foster Bodmeier Expert Report - G Meyer Expert Report - K	10/14/1988	European Patent Application EP 0 856 313 A1	BLS 031573	BLS 031608			
143	356 - Foster Bodmeier Expert Report - Y Meyer Expert Report - T	7/20/2001	Biovail Study No. 2463 A two-way, crossover, open-label, multiple-dose, fasting comparative bioavailability study between Diltiazem HCl extended-release capsules (2 x 180 mg) with morning drug administration and Diltiazem HCl extended-release capsules (2 x 180 mg) with evening drug administration in normal healthy non-smoking male and female subjects Vol. I of X	BLS 019938	BLS 020023			
144	358 - Foster	4/30/2001	Response to Official Action of November 3, 2000 Amendments and Remarks	BLS 028158 BLS 009062	BLS 028208 BLS 009066			
145	360 - Brenner	1989/00/00	James W. McGinity, Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms, Drugs and the Pharmaceutical Sciences, Volume 36			R		
146	361 - Brenner	0000/00/00	Structure of Sucrose			R		
147	365 - Brenner	9/11/2006	Rebuttal Expert Declaration of Professor Roland Bodmeier, Ph.D. with Exhibits A - G			R, U, H		
148	368 - Brenner	0000/00/00	Excerpts from book entitled "Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms" edited by James W. McGinity					
149	402 - Neutel	2001/08/00	Prescribing Information regarding Cardizem CD (diltiazem HCl)					
150	403 - Neutel	2000/12/00	Joel M. Neutel, Hypertension and its management: a problem in need of new treatment strategies, Journal of the Renin-Angiotensin-Aldosterone System, Volume 1, Supplement 2I					

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
151	404 - Neutel	2002/04/00	Stephen P. Glasser, et al., Efficacy and Safety of Diltiazem HCL Extended Release (G99) Dosed at Nighttime (10PM) Compared to Placebo and to Morning Dosing (8AM) in Moderate to Severe Essential Hypertension, American Journal of Hypertension, Volume 14, Number 4, Part 2 of 2					
152	405 - Neutel	1998/04/00	DHG Smith, et al., Pharmacokinetics of Identical Doses of Diltiazem Delivered via Different Long-Acting Delivery Systems in Hypertensive Patients, Antihypertensive Drug Treatment, Volume 11, Number 4, Part 2					
153	406 - Neutel	1997/04/00	DHG Smith, et al., Comparison of the Pharmacodynamic Profiles of Two Different Long-Acting Diltiazem Delivery Systems, ASH XII Abstracts, Volume 10, Number 4, Part 2					
154	407 - Neutel	2000/04/00	D.H.G. Smith, et al., The Antihypertensive Effects of Diltiazem 420 mg. A Comparison of Once Daily Delivery Systems, AJH, Volume 13, Number 4, Part 2					
155	408 - Neutel	2000/04/00	D.H.G. Smith, et al., The Pharmacokinetic and Hemodynamic Effects of Once Daily Diltiazem Delivery Systems, AJH, Volume 13, Number 4, Part 2					
156	1002 - Maes	12/12/1996	Biovail Study No. 1791 - A two-way, single-dose, open-label, fasting comparative bioavailability study of Diltiazem HCL Extended-Release 300 mg capsules versus Cardizem CD 300 mg capsules in normal healthy non-smoking male volunteers	BLS 030514	BLS 030566	R, U		
157	1003 - Maes Bodmeier Expert Report - X Meyer Expert Report - F	2/4/2004	Response to Official Action of August 4, 2003 Amendments and Remarks - Application No. 09/465,338	BLS 027559	BLS 027615			
158	1004 - Maes	7/2/1997	Biovail Study No. 1821 - A three-way steady-state, dose-proportionality study on Diltiazem HCL ER capsules (120, 240, 300 mg) In normal healthy non-smoking male volunteers	BLS 030415	BLS 030513	R, U		
159	Bodmeier Expert Declaration - A	0000/00/00	Curriculum Vitae of Professor Dr. Roland Bodmeier					

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
160	Bodmeier Expert Declaration - B	0000/00/00	A brief description and general consideration in understanding drug delivery systems including controlled/sustained/extended-release products			R, U, H		
161	Bodmeier Expert Declaration - D	1989/00/00	The Merck Index (11th Edition) "Diltiazem"					
162	Bodmeier Expert Declaration - E	2/9/1971	U.S. Patent No. 3,562,257					
163	Bodmeier Expert Declaration - F	1990/00/00	Physicians' Desk Reference (44th Edition) "Diltiazem" and "Cardizem"			R, U		
164	Bodmeier Expert Declaration - G	1990/00/00	Remington's Pharmaceutical Sciences (18th Edition) - Selected Chapters			R, U		
165	Bodmeier Expert Declaration - H	3/6/2000	Biovail Corporation v. Andrx Pharmaceuticals, 158 F. Supp. 2d 1318 (S.D. Fla. 2000)			R, U		
166	Bodmeier Expert Declaration - I	2/13/2001	Biovail Corporation v. Andrx Pharmaceuticals, 239 F.3d 1297 (2001)			R, U		
167	Bodmeier Expert Declaration - J	5/28/1993	Patent Application No. 07/721,396 of Arthur M. Deboeck, et al. -- Preliminary Amendment					
168	Bodmeier Expert Declaration - K	4/20/1993	Patent Application No. 07/721,396 of Arthur M. Deboeck, et al. -- Declaration Under 37 C.F.R. 1.132					
169	Bodmeier Expert Declaration - O Porter Expert - F	10/14/1988	E.P. Patent No. 0 320 097 A1					
170	Bodmeier Expert Declaration - P	2000/00/00	Handbook of Pharmaceutical Excipients (3rd Edition) "Sugar Spheres"					
171	Bodmeier Expert Declaration - Q	1/1/1990	USP XXII The United States Pharmacopeia (22nd Revision) "Diltiazem"			R, U		
172	Bodmeier Expert Declaration - R	1990/00/00	Remington's Pharmaceutical Sciences (18th Edition) Chapter 19 - Disperse Systems			R, U		
173	Bodmeier Expert Declaration - S	1989/00/00	Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms -- Chapter 2 - Aqueous Polymeric Coating for Modified-Release Pellets			R, U		
174	Bodmeier Expert Declaration - T	5/1/2006	Letter from Megan Severinsen to Steven Maddox in response to the Subpoena Duces Tecum served upon Rohm America enclosing product brochures for various EUDRAGIT products					

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
175	Bodmeier Rebuttal Expert Declaration - A	0000/00/00	List of Experiments conducted under Dr. Bodmeier's direction and supervision			R, U, H		
176	Bodmeier Rebuttal Expert Declaration - B	1990/00/00	General Chemistry (3rd Edition) "solubility"			R, U		
177	Bodmeier Rebuttal Expert Declaration - C-1	4/6/2005	PRACS Study R04-1764 (Diltiazem hydrochloride)					
178	Bodmeier Rebuttal Expert Declaration - C-2	4/6/2005	PRACS Study R04-1765 (Diltiazem hydrochloride)					
179	Bodmeier Rebuttal Expert Declaration - D	6/3/2003	Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery, J. Pharmacy and Pharmaceut Sci			R, U		
180	Bodmeier Rebuttal Expert Declaration - E	7/12/2001	pH-metric solubility. 3. Dissolution titration template method for solubility determination, European Journal of Pharmaceutical Sciences			R, U		
181	Bodmeier Rebuttal Expert Declaration - F	1985/02/00	Effect of Diffusion Layer pH and Solubility on the Dissolution Rate of Pharmaceutical Bases and Their Hydrochloride Salts I: Phenazopyridine, American Pharmaceutical Association			R, U		
182	Bodmeier Rebuttal Expert Declaration - G	1996/08/00	Xiaodi Guo, M.S. Dissertation, Physicochemical and Mechanical Properties Influencing the Drug Release from Coated Dosage Forms			R, U		
183	Bodmeier Expert Report - F	0000/00/00	Claim 1 of the '866 Patent			U		
184	Bodmeier Expert Report - H	1996/00/00	Physicians' Desk Reference (50th Edition), Cardizem					
185	Bodmeier Expert Report - I	1998/00/00	Physicians' Desk Reference (52nd Edition), Tiazac					
186	Bodmeier Expert Report - J	5/15/1994	The Influence of Time of Administration on The Pharmacokinetics of a Once-a-Day Diltiazem Formulation: Morning Against Bedtime, Biopharmaceutics & Drug Disposition					

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
187	Bodmeier Expert Report - K	2/14/1991	Pharmacokinetic Properties and Antihypertensive Efficacy of Once-Daily Diltiazem, Journal of Cardiovascular Pharmacology					
188	Bodmeier Expert Report - L	1997/00/00	Effect of Morning Versus Evening Dosing of Diltiazem on Myocardial Ischemia Detected by Ambulatory Electrocardiographic Monitoring in Chronic Stable Angina Pectoris, The American Journal of Cardiology					
189	Bodmeier Expert Report - M	10/30/1996	Administration-Time-Dependent Effects of Diltiazem on the 24-Hour Blood Pressure Profile of Essential Hypertension Patients, Chronobiology International					
190	Bodmeier Expert Report - N	1998/00/00	Physicians' Desk Reference (52nd Edition), Covera-HS			R, U		
191	Bodmeier Expert Report - O	11/3/1992	U.S. Patent No. 5,160,744			R		
192	Bodmeier Expert Report - P	8/3/1993	U.S. Patent No. 5,232,705			R		
193	Bodmeier Expert Report - R	1/15/2007	Excerpt from Deposition Transcript of Edith Mathiowitz			U, H		
194	Bodmeier Expert Report - S	0000/00/00	Eudragit E30D New Product Denomination - Rohm Pharma	BLS 030729	BLS 030736			
195	Bodmeier Expert Report - T	1986/00/00	Handbook of Pharmaceutical Excipients, Polymethacrylates					
196	Bodmeier Expert Report - U	1989/00/00	Drugs and the Pharmaceutical Sciences, Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms			R, U		
197	Bodmeier Expert Report - V	5/25/2001	Patent Application No. 09/567,451 - Office Action Summary					
198	Bodmeier Expert Report - Z	0000/00/00	NDA 21-392 - Diltiazem Hydrochloride Extended-Release Tablets Volume 15 of 48	BLS 019378	BLS 019440			
199	Bodmeier 2 Expert Report - B	1/26/2007	Excerpt from Deposition Transcript of Kenneth Albert			DU, U		
200	Bodmeier 2 Expert Report - C	1989/00/00	International Journal of Pharmaceutics, Dissolution kinetics of commercially available controlled-release theophylline preparations			R, U		

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
201	Bodmeier 2 Expert Report - D	8/30/1993	The use of dissolution rate data to account for differences in the absorption profiles of two controlled/modified-release capsule dosage forms of indomethacin in human volunteers, International Journal of Pharmaceutics			R, U		
202	Bodmeier 2 Expert Report - E	12/18/1999	Evaluation of floating and sticking extended release delivery systems: an unconventional dissolution test, Journal of Controlled Release			R, U		
203	Bodmeier 2 Expert Report - F	3/27/2000	A Better Dissolution Method for Ranitidine Tablets USP, Pharmaceutical Development and Technology			R, U		
204	Bodmeier 2 Expert Report - G	1/1/1995	The United States Pharmacopeia, Diltiazem hydrochloride					
205	Bodmeier Supp. Expert Report - A	12/22/2000	Validation Report for the Diltiazem HCl Active Pellets (TZ) Product Code No. 149	ANDCLA 109743	ANDCLA 109753	R, U, C		
206	Bodmeier Supp. Expert Report - B	5/5/2003	Process Validation Report for Diltiazem HCl Active Pellets (TZ) Product Code No. 149*1	ANDCLA 109901	ANDCLA 109910	R, U, C		
207	Bodmeier Supp. Expert Report - C	1/23/2002	Process Validation Report for Diltiazem HCl Extended Pellets (TZ) Product Code No. 151	ANDCLA 111278	ANDCLA 111437	R, U, C		
208	Bolton Declaration - A Bolton Expert Report - A	0000/00/00	Curriculum Vitae of Sanford M. Bolton, Ph.D.					
209	Bolton Declaration - C	0000/00/00	Biovail Contract Research - Table 9D - Table 9G (pages 042-044)	BLS 020426	BLS 020428	NPI		
210			EXHIBIT REMOVED					
211	Bolton Expert Report - C	4/20/2007	Declaration of Sanford M. Bolton, Ph.D. in Support of Andrx Pharmaceuticals, LLC's and Andrx Corporation's Claim Construction			U, H		
212	Bolton Expert Report - D	4/6/2005	Andrx Pharmaceuticals (ANDA No. 77-686) Diltiazem Hydrochloride Extended-Release Tablets, 420 mg (Book 3 of 38)	ANDCLA 01036 ANDCLA 07624	ANDCLA 01560 ANDCLA 08140			

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
213	Bolton Expert Report - E	0000/00/00	Statistical Analysis of Data generated in the two Andrx studies (Confidence Intervals - Reference fed vs fast/Test fed vs fast)			R, U, H		
214	Cheng Declaration - A	0000/00/00	Pages from ANDA 75-401 that summarize the manufacturing procedures, ingredients and components of the diltiazem HCl active pellets in Andrx's generic version of TIAZAC product	ANDCLA 69736	ANDCLA 69748	R, U, H		
215	Cheng Declaration - B	0000/00/00	Pages from ANDA 75-401 that summarize the manufacturing procedures, ingredients and components of the diltiazem HCl extended-release pellets in Andrx's generic version of TIAZAC product	ANDCLA 69751	ANDCLA 69770	R, U, H		
216	Cheng Declaration - C	0000/00/00	Pages from ANDA 77-686 that summarize the manufacturing procedures, ingredients and components of the diltiazem HCl active pellets in Andrx's generic version of the CARDIZEM LA product	ANDCLA 00398	ANDCLA 00416	R, U, H		
217	Cheng Declaration - D	0000/00/00	Pages from ANDA 77-686 that summarize the manufacturing procedures, ingredients and components of the diltiazem HCl extended-release pellets in Andrx's generic version of the CARDIZEM LA product	ANDCLA 00419	ANDCLA 00437	R, U, H		
218	Meyer Expert Report - A	0000/00/00	Curriculum Vitae of Marvin C. Meyer, Ph.D.					
219	Meyer Expert Report - B	0000/00/00	List of Documents reviewed in preparation of report			U, R, H		
220	Meyer Expert Report - D	2005/00/00	FDA Orange Book (Food and Drug Administration, Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition, pages referring to Bioavailability					
221	Meyer Expert Report - H	11/22/2001	Submissions Accompanying Request for Continued Examination (RCE) - Application No. 09/567,451	BLS 028330	BLS 028392			
222	Meyer Expert Report - I	0000/00/00	FOI Services, Inc. Guidance Oral Extended (Controlled) Release Dosage Forms In Vivo Bioequivalence and In Vitro Dissolution Testing					
223	Meyer Expert Report - J	7/1/1992	FOI Services, Inc. Guidance Statistical Procedures for Bioequivalence Studies Using a Standard Two-Treatment Crossover Design July, 1, 1992					
224	Meyer Expert Report - L	5/25/2001	Office Action Summary - Application No. 09/567,451					

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
225	Meyer Expert Report - O	1996/00/00	Physicians' Desk Reference, 50th Edition - Pages referencing Cardizem					
226	Meyer Expert Report - P	2001/10/00	Biovail Study #2464 - A Two-Way, Crossover, Open-Label, Multiple-Dose, Fasting, Comparative Bioavailability Study Between Diltiazem HCL Extended-Release Bead Tablets (360 mg) with Evening Drug Administration (10:00 pm) and Diltiazem HCL Extended-Release Bead Tablets (360 mg) with Morning (8:00 am) Drug Administration in Normal Healthy Non-Smoking Male and Female Subjects	BLS 020384 BLS 035166	BLS 020684			
227	Meyer Expert Report - Q	1996/00/00	Jean Thiffault, et al., The Influence of Time of Administration on the Pharmacokinetics of a Once-a-day Diltiazem Formulation: Morning Against Bedtime, Biopharmaceutics & Drug Disposition, Volume 17, 107-115					
228	Meyer Expert Report - R	7/21/2003	IKP Study No. 020/03-03 DM - Bioavailability Study on Daytime and Nighttime Use of Tizac Capsules 360 mg in Healthy Subjects	BLS 053034	BLS 053096			
229	Meyer Expert Report - S	7/4/2001	Biovail Study No. 2434 - A Two-Way, Crossover, Open-Label, Single-Dose, Fasting, Comparative Bioavailability Study of Diltiazem Hydrochloride 360 mg Extended-Release Bead Tablets Under Morning Administration Versus Evening Administration Conditions in Normal Healthy Non-Smoking Male and Female Subjects	BLS 019849	BLS 19913			
230	Meyer Expert Report - U	1997/04/04	Biovail Study No. P97-062 - A Multiple Dose Relative Bioavailability Study of Diltiazem HCL ER 300 mg Capsules Versus Cardizem CD 300 mg Capsules Under Fasting Conditions	BLS 063095	BLS 063234			
231	Meyer Expert Report - V	1997/00/00	Physicians' Desk Reference, 51st Edition - Pages referencing Cardizem					
232	Meyer Expert Report - W	4/11/1997	Biovail Study No. 1848 - A Three-Way, Single-Dose, Open-Label, Food-Effect Comparative Bioavailability Study of Diltiazem HCL Extended-Release 300 mg Capsules Versus Cardizem CD 300 mg Capsules in Normal Healthy Non-Smoking Male Volunteers	BLS 0066956	BLS 067011			
233	Meyer Expert Rebuttal - A	2005/04/00	ANDA Product: Proposed labeling for Cardizem LA	ANDCLA 00065 ANDCLA 14222	ANDCLA 00104 ANDCLA 14261			

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
234	Meyer Expert Rebuttal - B	1/26/2007	Deposition Transcript of Kenneth Albert, Ph.D.			DU, U		
235	Meyer Expert Rebuttal - C	3/13/2007	Deposition Transcript of Alan Copa					
236	Meyer Expert Rebuttal - D	4/5/2007	Initial Expert Report of Professor Roland Bodmeier, Ph.D. regarding U.S. Patent No. 7,108,866			U, H		
237	Meyer Expert Rebuttal - E	5/3/2007	Expert Report of Sanford M. Bolton, Ph.D. regarding U.S. Patent No. 7,108,866 with Exhibits A - E			U, H		
238	Meyer Expert Rebuttal - F	0000/00/00	Summary chart prepared by Meyer from data generated by various biostudies			U, H, C		
239	Niemczyk Expert Declaration - A	0000/00/00	Curriculum Vitae of Thomas M. Niemczyk, Ph.D.					
240	Niemczyk Expert Declaration - B	0000/00/00	Comparison of two Diltiazem HCL spectra					
241	Niemczyk Expert Declaration - D	3/6/2000	Biovail Corporation International, et al., v. Andrx Pharmaceuticals, Inc., 158 F. Supp. 2d 1318 (S.D. Fla. 2000)			DU, U		
242	Niemczyk Expert Declaration - E	2/13/2001	Biovail Corporation International, et al., v. Andrx Pharmaceuticals, Inc., 239 F.3d 1297 (Fed. Cir. 2001)			DU, U		
243	Niemczyk Expert Declaration - F	0000/00/00	Graphic showing IR features of ethylcellulose			A, F		
244	Niemczyk Expert Declaration - G	0000/00/00	TIR plot					
245	Niemczyk Supplementary Expert Declaration - 1	0000/00/00	Three typical examples of spectra in the data set: RN0303101sugarspheresNF303529DRY.2					
246	Niemczyk Supplementary Expert Declaration - 2	0000/00/00	Two examples of spectra from the RN0303101sugarspheresNF303529DRY.4 data set with a reference spectrum of sugar spheres					
247	Niemczyk Supplementary Expert Declaration -3	0000/00/00	Three spectra contained in Exhibit 2 replotted					

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
248	Niemczyk Supplementary Expert Declaration - 4	0000/00/00	Examples of one of the data sets in the series taken from pellets exposed to 0.1M HCL for two hours, titled "Diltiazem 120mg690R020A2hours0_1Hcl.4"					
249	Niemczyk Supplementary Expert Declaration - 5	0000/00/00	A selection of spectra from the data set titled "Diltiazem 120mg690R020A2hours0_1HCl.1" overlaid with the spectrum ATR1					
250	Niemczyk Supplementary Expert Declaration - 6	0000/00/00	Spectra contained in Exhibit 5 replotted					
251	Niemczyk Supplementary Expert Declaration - 7	0000/00/00	Plot containing several spectra from the data set titled Diltiazem 120 mg 690R020A2hours)_1Hcl.2					
252	Niemczyk Supplementary Expert Declaration - 8	0000/00/00	Collection of spectra taken from data set titled Diltiazem 120mg690R020A2hours0_1Hcl+30mins5_8.5					
253	Porter Expert Report - A	0000/00/00	Curriculum Vitae of Stuart C. Porter					
254	Porter Expert Report - G	1990/00/00	Excerpts from Remington's Pharmaceutical Sciences, 18th Edition					
255	Porter Expert Report - H	1989/00/00	Merck Index entry of diltiazem, 11th Edition			DU		
256	Porter Expert Report - I	1/1/1990	United States Pharmacopia, XXII (describes a monograph for diltiazem products)			DU		
257	Porter Expert Report - J	1990/00/00	Excerpts from The Physician's Desk Reference, 44th Edition					
258	Porter Expert Report - K	5/1/2006	The Handbook of Pharmaceutical Excipients; Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms; manufacturer's literature -- Eudragit brochures					
259	Porter Expert Report - L	0000/00/00	Selected Results from a Literature Search			R, U, H, A		

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
260	Porter Expert Report - M	3/6/2000	Biovail Corp. Int'l v. Andrx Pharmaceuticals, Inc., 158 F. Supp.2d 1318 (S.D. Fla. 2000)			DU, R, U		
261	Porter Expert Report - N	2000/00/00	Excerpts from Handbook of Pharmaceutical Excipients, 3rd Edition; USP XXII					
262	Porter Expert Report - O	1990/00/00	Chapter 19 of Remington's Pharmaceutical Sciences, 18th Edition					
263	Weiner Expert Report - A	0000/00/00	Curriculum Vitae of Norman Weiner, Ph.D.					
264	Weiner Expert Report - B	0000/00/00	List of cases Norman Weiner, Ph.D. testified in as an expert witness at deposition or at trial			R, U, H		
265	Weiner Expert Report - C	0000/00/00	ANDA 77-686 <i>In Vitro</i> Dissolution Data					
266	Weiner Expert Report - E	2003/00/00	Handbook of Pharmaceutical Excipients, 4th Edition, excerpts regarding Ethylcellulose, Polyvidone and Sugar Spheres					
267	Weiner Expert Report - F	3/6/2000	Biovail Corporation International, et al., v. Andrx Pharmaceuticals, Inc., 158 F. Supp. 2d 1318 (S.D. Fla. 2000)			DU, R, U		
268	Weiner Expert Report - G	1993/00/00	Hawley's Condensed Chemical Dictionary, Twelfth Edition - page describing, wetting agent					
269	Weiner Expert Report - H	0000/00/00	Physical Pharmacy, Fourth Edition, Physical Chemical Principles in the Pharmaceutical Sciences, Fourth Edition - page describing: wetting agent					
270	Weiner Expert Report - I	0000/05/28 (illegible)	Preliminary Amendment - Deboeck et al., Extended Release Form of Diltiazem ('791 patent)			DU, U		
271	Weiner Expert Report - J	8/5/2003	Md. Selimreza, et al., Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery, J Pharm Pharmaceut Sci, 282 (2003)					
272	Weiner Expert Report - K	2001/00/00	The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals - Thirteenth Edition - page referencing Diltiazem					
273	Weiner Expert Report - L	2001/00/00	The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals - Thirteenth Edition - page referencing Sucrose					
274	Wu Expert Declaration - A	0000/00/00	Curriculum Vitae of Chuan-Yu Wu, Ph.D.					
275	Wu Expert Declaration - B	0000/00/00	List of Documents sent to Chaun-Yu Wu, Ph.D. for review			R, H		

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
276	Wu Expert Declaration - C	10/21/2004	Paper presented in EuroPM 2004: Measurement of density variations in Compacted Parts and Filled Dies using X-ray Computerized Tomography			R		
277	Wu Expert Declaration - D	4/25/2005	C.-Y. Wu, et al., Modelling the mechanical behavior of pharmaceutical powders during compaction, Powder Technology 152 (2005) 107-117, http://www.sciencedirect.com					
278	Wu - Expert Declaration - E	0000/00/00	C.-Y. Wu, et al. Modelling Packing and Compaction of Pharmaceutical Powders: A Combined Numerical and Experimental Study, Pfizer Institute for Pharmaceutical Materials Science, University of Cambridge					
279	Wu Expert Declaration - F	0000/00/00	X-ray Images of Diltiazem					
280		11/27/2006	Defendants' Motion for Summary Judgment of Non-Infringement of U.S. Patent No. 5,529,791					
281		11/27/2006	Memorandum in Support of Defendants' Motion for Summary Judgment of Non-Infringement of U.S. Patent No. 5,529,791 with Exhibits					
282		1/19/2007	Biovail's Answering Brief in Opposition to Andrx's Motion for Summary Judgment of Non-Infringement of the '791 Patent and Opening Brief in Support of its Cross-Motion for Summary Judgment of No Collateral Estoppel					
283		1/19/2007	Declaration of Preston K. Ratliff II in Support of Biovail's Answering Brief in Opposition to Andrx's Motion for Summary Judgment of Non-Infringement of the '791 Patent and Opening Brief in Support of its Cross-Motion for Summary Judgment of No Collateral Estoppel with Exhibits					
284		1/19/2007	Biovail's Cross-Motion for Summary Judgment of No Collateral Estoppel					
285	Bodmeier Expert Declaration	7/6/2006	Expert Declaration of Professor Roland Bodmeier, Ph.D. with Exhibits A - T			U, H		
286	Bodmeier Expert Report	4/5/2007	Initial Expert Report of Professor Roland Bodmeier, Ph.D. Regarding United States Patent No. 7,108,866 with Exhibits A - Z			DU, U, H		

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
287	Bodmeier 2 Expert Report	5/11/2007	Initial Expert Report of Professor Roland Bodmeier, Ph.D. Regarding United States Patent No. 7,108,866 with Exhibits A - G			DU, U, H		
288	Bodmeier Supp. Expert Report	8/2/2007	Supplemental Expert Report of Professor Roland Bodmeier, Ph.D. Regarding United States Patent No. 7,108,866 with Exhibits A - C			DU, U, H		
289	Bolton Declaration	4/20/2007	Declaration of Sanford M. Bolton, Ph.D. in Support of Andrx Pharmaceuticals, LLC's and Andrx Corporation's Claim Construction with Exhibits A - C			DU, R, U, H		
290	Bolton Expert Report	5/3/2007	Expert Report of Sanford M. Bolton, Ph.D. Regarding United States Patent No. 7,108,866 with Exhibits A - E			DU, U, H		
291	Cheng Declaration	11/22/2006	Declaration of Xiu-Xiu Cheng with Exhibits A - D			DU, R, U, H		
292	Meyer Expert Report	4/6/2007	Expert Report of Marvin C. Meyer, Ph.D. with Exhibits A - Y			DU, U, H		
293	Meyer Expert Rebuttal Report	5/10/2007	Expert Rebuttal Report of Marvin C. Meyer, Ph.D. with Exhibits A - F			DU, U, H		
294	Porter Expert Report	7/3/2006	Expert Report of Stuart C. Porter, B. Pharm., Ph.D. with Exhibits A - O					
295	Weiner Expert Report	9/11/2006	Expert Report of Norman Weiner with Exhibits A - L					
296		0000/00/00	Physical Samples of Andrx Pellets and/or Tablets			R, NPI		
297		0000/00/00	Any Exhibits Identified by Plaintiff					
298		3/20/2007	Defendants Andrx Pharmaceuticals, LLC's and Andrx Corporation's Motion for Leave to File First Amended Answer, Affirmative Defenses, and Counterclaims with Exhibits					
299		11/20/2006	Biovail's Responses to Defendant Andrx's First Set of Requests for the Production of Documents and Things			R, U		
300		2/5/2007	Biovail's Responses to Defendant Andrx's Second Set of Interrogatories			R, U		
301		7/7/2006	Expert Report of Gerald S. Brenner, Ph.D., Regarding Andrx's Infringement of the '791 Patent			NPI, C		
302		9/8/2006	Rebuttal Expert Report of Gerald S. Brenner, Ph.D.			NPI, C		
303		1/19/2007	Declaration of Gerald S. Brenner, Ph.D.			NPI, C		

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
304		3/6/2007	Supplement to the Expert Report of Gerald S. Brenner, Ph.D., Regarding Andrx's Infringement of the '791 Patent			NPI, C		
305		3/30/2007	Declaration of Gerald S. Brenner, Ph.D. in Support of Biovail's Opening Claim Construction Brief			NPI, C		
306		4/9/2007	Expert Report of Gerald S. Brenner, Ph.D., Regarding Andrx's Infringement of the '866 Patent			NPI, C		
307		5/11/2007	Rebuttal Expert Report of Gerald S. Brenner, Ph.D., Regarding Andrx's Infringement of the '866 Patent			NPI, C		
308		6/29/2007	Rebuttal Expert Report of Gerald S. Brenner, Ph.D., on the Issue of Alleged Inequitable Conduct in Obtaining the '866 Patent			NPI, C		
309		6/7/2006	Affirmative Expert Report of Martyn C. Davies, Ph.D.			NPI, C		
310		4/9/2007	Expert Report of Thomas S. Foster, Pharm.D., Regarding Andrx's Infringement of the '866 Patent			NPI, C		
311		5/11/2007	Rebuttal Expert Report of Thomas S. Foster, Pharm.D. Regarding the '866 Patent			NPI, C		
312		6/29/2007	Rebuttal Expert Report of Thomas S. Foster, Pharm.D., on the Issue of Alleged Inequitable Conduct in Obtaining the '866 Patent			NPI, C		
313		9/11/2006	Expert Report of Joel M. Neutel, M.D.			NPI, C		
314		5/24/2007	Plaintiff's Slide Presentation Regarding '791 Patent			NPI		
315		5/24/2007	Plaintiff's Slide Presentation Regarding '866 Patent			NPI		
316		5/24/2007	Plaintiff's '791 Patent Animations			NPI		
317		5/24/2007	Markman Hearing Transcript					
318		1997/00/00	James W. McGinity, Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms, Drugs and the Pharmaceutical Sciences, Second Edition, Revised and Expanded, Volume 79, Chapters 3 and 5			R, U		
319		6/26/1991	Certified File Wrapper: Application No. 07/721,396; Patent No. 5,288,505			NPI, C		
320		5/28/1993	Certified File Wrapper: Application No. 08/068,951			NPI, C		
321		1/15/1995	EP Patent No. 0 318 398 B1 and translation			R, U		
322		3/26/2007	Final Joint Claim Construction Charts			R		
323		3/30/2007	Biovail's Opening Claim Construction Brief			R		
324		3/30/2007	Defendant's Opening Brief on Claim Construction			R		

ANDRX DEFENDANTS' TRIAL EXHIBIT LIST

DEF. TRIAL EXHIBIT NO.	DEPOSITION/ EXPERT EXHIBIT NO.	DATE	DESCRIPTION	BEGIN BATES NO.	END BATES NO.	OBJECTED	IDENTIFIED	ADMITTED
325		4/24/2007	Joint Appendix of Intrinsic and Extrinsic Evidence					
326		4/24/2007	Biovail's Answering Claim Construction Brief			R		
327		4/24/2007	Defendant's Answering Brief on Claim Construction			R		
328		6/7/2007	Order regarding claim terms					
329	Foster Expert Report - 7	4/26/2001	Study #2370 (B00-457PK-DILG99)	BLS 019146	BLS 019281			
330	Foster Expert Report - 17	4/6/2005	Pracs -- Diltiazem Hydrochloride (R04-1764) Final Report	ANDCLA 01042	ANDCLA 01129			
331	Foster Expert Report - 18	4/6/2005	Pracs -- Diltiazem Hydrochloride (R04-1765) Final Report	ANDCLA 07630	ANDCLA 07715			
332	DTX 4 Meyer Expert Report - G	4/11/2005	Reply, Amendments and Submission of Affidavit by Edith Mathiowitz, Ph.D. and Exhibits	BLS 031469	BLS 031770	DU		
333		5/24/2007	Defendants' Slide Presentation Regarding '791 Patent			R, U		
334		5/24/2007	Defendants' Slide Presentation Regarding '866 Patent			R, U		
335		6/7/2006	Andrx Process Validation Report No. 1052PTC	ANDCLA 111438	ANDCLA 111495	R, U		